Comparing the safety profile of Teliso-V with other ADCs in lung cancer скачать в хорошем качестве

Comparing the safety profile of Teliso-V with other ADCs in lung cancer

Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses the differences in the onset of sensory neuropathy between antibody-drug conjugates (ADCs) with the MMA payload, noting that ADCs with the MMA payload have a faster onset of sensory neuropathy compared to ADCs with telisotuzumab vedotin (Teliso-V). The presence of the antibody and linker in the ADC may contribute to the delayed onset of sensory neuropathy, implying that the Teliso-V payload may have a superiority in this aspect. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.